Losmapimod, an Oral Anti-p38 MAP Kinase, Demonstrates Anti-Neuropathic and Anti-Inflammatory Effects in Rat Acute Pain
Mickael Soued, Leila Hamdi, Mouna Ben Rehouma, Jean-Xavier Mazoit, Dan Benhamou · 2026
Read Losmapimod, an Oral Anti-p38 MAP Kinase, Demonstrates Anti-Neuropathic and Anti-Inflammatory Effects in Rat Acute Pain by Mickael Soued, Leila Hamdi, Mouna Ben Rehouma, Jean-Xavier Mazoit, Dan Benhamou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13257725.txt.
Description
Mickael Soued and co-authors test an oral kinase blocker against early nerve pain and inflammation in rats in a 2026 study. Losmapimod blocks p38 MAP kinase, a signal involved in pain processing. Nerve ligation created acute neuropathic pain, while a paw injection model tested inflammatory pain over several days.
The drug eased heat and touch sensitivity from the first days after nerve injury. Its effective dose beat gabapentin's on a weight basis, and combining the two added effects without synergy surprises. Against inflammation, the drug shrank paw swelling as strongly as a standard anti-inflammatory medicine. Prior human work suggests good tolerance of the compound. Surgeons face pain that mixes nerve and inflammatory parts after operations, and the authors propose this drug as a candidate worth clinical testing for that window.
Catalog record
| CREATOR | Mickael Soued, Leila Hamdi, Mouna Ben Rehouma, Jean-Xavier Mazoit, Dan Benhamou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |